Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12P AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/047575MODIFIED CORONAVIRUS STRUCTURAL PROTEIN
WO 10.03.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CA2021/051201 Applicant MEDICAGO INC. Inventor LAVOIE, Pierre-Olivier
Modified coronaviras spike (S)-protein, virus-like particle (VLPs) comprising the modified S protein and nucleic acids encoding modified S protein are provided. Methods for modified S-protein and VLP production in a host or host cell are also described. The modified S-protein may comprise a transmembrane domain (TM) or portion of a TM, and a cytosolic tail (CT) or of a CT, wherein the CT or portion of the CT is derived from an influenza hemagglutinin (HA) protein and wherein the TM or portion of the TM is heterologous to the CT or portion of the CT. In addition a method for inducing immunity to a coronaviras infection in a subject, comprising administering a composition comprising the modified coronaviras (S)-protein or VLP to the subject is described.
2.WO/2021/211414BISPECIFIC ANTIBODY COMPOSITIONS AND METHODS FOR TREATING COVID-19
WO 21.10.2021
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/US2021/026811 Applicant MADDON ADVISORS LLC Inventor MADDON, Paul J.
This invention provides a bispecific antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically binds to the extracellular portion of human TMPRSS2 (hTMPRSS2); (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide; and (iv) specifically inhibits the entry into hACE2+/hTMPRSS2+ human cells of a pseudovirus bearing SARS-CoV-2 S protein. This invention also provides related pharmaceutical compositions, recombinant nucleic acid molecules, vectors, AAV particles, therapeutic and prophylactic methods, and kits.
3.WO/2021/236651COMPOSITIONS AND METHODS OF A NUCLEASE CHAIN REACTION FOR NUCLEIC ACID DETECTION
WO 25.11.2021
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/US2021/032977 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor SAVAGE, David
Described herein are nucleic acid detection compositions and systems comprising an internal nuclease chain reaction (NCR) for signal amplification and methods of using these NCR-containing compositions and systems.
4.WO/2022/081971NOTCH4 ANTIBODIES AND USES THEREOF
WO 21.04.2022
Int.Class C12P 21/08
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
08Monoclonal antibodies
Appl.No PCT/US2021/055181 Applicant THE CHILDREN'S MEDICAL CENTER CORPORATION Inventor CHATILA, Talal
Provided herein are anti-Notch4 antibodies or antigen binding fragments thereof and their use in the treatment of a disease or disorder associated with increased levels of Notch4.
5.WO/2021/231751FUCOSYLATED OLIGOSACCHARIDES FOR PREVENTION OF CORONAVIRUS INFECTION
WO 18.11.2021
Int.Class C07H 5/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
5Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
04to nitrogen
06Aminosugars
Appl.No PCT/US2021/032283 Applicant GLYCOSYN LLC Inventor MORROW, Ardythe, L.
The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection and/or to promote recovery from a respiratory pathogen infection in the respiratory system and/or the GI tract of a subject.
6.WO/2021/207962ANTIBODIES TO SARS-CORONAVIRUS (COVID-19) S1 SPIKE PROTEIN
WO 21.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2020/084857 Applicant ACTIVE MOTIF SHANGHAI LIMITED Inventor LU, Yanan
Provided are recombinant monoclonal antibodies that bind to the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2 or COVID-19) spike protein and using methods thereof. The antibodies can inhibit or neutralize SARS-CoV-2 activity, thus can be used for treating or preventing or diagnosing COVID-19 infection in humans.
7.WO/2021/195326HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
WO 30.09.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2021/024072 Applicant VANDERBILT UNIVERSITY Inventor CROWE Jr., James E.
The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
8.WO/2021/202952COMPOSITIONS INCORPORATING SULFATED POLYSACCHARIDES FOR INHIBITING SARS-COV-2
WO 07.10.2021
Int.Class A61K 31/727
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
726Glycosaminoglycans, i.e. mucopolysaccharides
727Heparin; Heparan
Appl.No PCT/US2021/025500 Applicant LINHARDT, Robert, John Inventor LINHARDT, Robert, John
The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μΜ, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.
9.WO/2021/257494METHODS FOR MODULATING TLR4 SIGNALING
WO 23.12.2021
Int.Class A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Appl.No PCT/US2021/037310 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor KASPER, Dennis L.
Provided herein are methods of use involving Bacteroides glycolipid compositions.
10.WO/2021/183961EXOSOMAL NUCLEIC ACID VACCINE MODULARLY CONFIGURED TO HARNESS MULTIPLE ANTIGEN PRESENTATION MECHANISMS
WO 16.09.2021
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Appl.No PCT/US2021/022222 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor GOULD, Stephen John
The present invention relates to modular systems for vaccination against infectious agents that involves the delivery of, e.g., exosome-loaded, antigen-encoding mRNAs to and into cells and tissues of the immunized subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of vaccines, e.g., nucleic acid vaccines, loaded into extracellular vesicles, e.g., exosomes loaded with synthetic mRNAs encoding multiple surface and cytoplasmic antigens of interest, e.g., antigenic polypeptides derived from an infectious virus, e.g., SARS-CoV-2, designed to elicit strong humoral and cellular immune responses due to the simultaneous expression of antigens in their native state and as exosome-associated antigens.